Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05256381 · ClinicalTrials.gov registry record · Phase 2
A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors
A Phase 2 study, sponsored by SOTIO Biotech.
- Terminated
- Registry status
- Phase 2
- Development phase
- 166
- Enrollment target
NCT05256381 is a Phase 2 study that was terminated before completion, run by SOTIO Biotech. The registered enrollment target is 166 participants.
The verdict
NCT05256381, a Phase 2 study, was terminated before completion, sponsored by SOTIO Biotech.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 166 participants
- Enrollment target
Study Summary
The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
Interventions
- DRUG Pembrolizumab
- DRUG Nanrilkefusp Alfa
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 166 participants |
| Start Date | 2022-06-21 |
| Est. Completion | 2024-11-29 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05256381
The ClinicalTrials.gov registry entry for NCT05256381 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 166 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is SOTIO Biotech, which has 3 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT05256381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05256381 about?
NCT05256381 is a clinical study titled "A Study of SOT101 in Combination With Pembrolizumab to Evaluate the Efficacy and Safety in Patients With Selected Advanced Solid Tumors". The primary objective of the study is to estimate the antitumor efficacy of nanrilkefusp alfa in combination with pembrolizumab in selected tumors.
What is the current status of trial NCT05256381?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 166 participants. The study started on 2022-06-21. Estimated completion is 2024-11-29.
What interventions are being tested in trial NCT05256381?
The interventions under investigation include: Pembrolizumab (DRUG), Nanrilkefusp Alfa (DRUG).
Who is sponsoring clinical trial NCT05256381?
This trial is sponsored by SOTIO Biotech, which has 3 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.